celecoxib has been researched along with HPV Infection in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite 3 years of treatment, the papillomatosis proved difficult to control, requiring a procedure approximately every 3 months." | 1.51 | Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis. ( Bentley, PL; Coulter, MJ; Nelson, BL, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Rojas-Lechuga, MJ | 1 |
| Remacha, J | 1 |
| González-Sánchez, N | 1 |
| Grau, JJ | 1 |
| Castillo, P | 1 |
| Haag, O | 1 |
| Vilaseca, I | 1 |
| Bentley, PL | 1 |
| Coulter, MJ | 1 |
| Nelson, BL | 1 |
| Rader, JS | 1 |
| Sill, MW | 1 |
| Beumer, JH | 1 |
| Lankes, HA | 1 |
| Benbrook, DM | 1 |
| Garcia, F | 1 |
| Trimble, C | 1 |
| Tate Thigpen, J | 1 |
| Lieberman, R | 1 |
| Zuna, RE | 1 |
| Leath, CA | 1 |
| Spirtos, NM | 1 |
| Byron, J | 1 |
| Thaker, PH | 1 |
| Lele, S | 1 |
| Alberts, D | 1 |
| Lucs, AV | 1 |
| Wu, R | 1 |
| Mullooly, V | 1 |
| Abramson, AL | 2 |
| Steinberg, BM | 2 |
| Rosenthal, DW | 1 |
| DeVoti, JA | 1 |
| Bonagura, VR | 1 |
| Farley, JH | 1 |
| Truong, V | 1 |
| Goo, E | 1 |
| Uyehara, C | 1 |
| Belnap, C | 1 |
| Larsen, WI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)[NCT00081263] | Phase 2 | 130 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Whether or not patients with CIN 2/3 or CIN 3 upon entry experience a complete remission (or partial regression to CIN 1) in the post-treatment excisional biopsy. (NCT00081263)
Timeframe: Post treatment evaluation was done 14 to 18 weeks after treatment randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Celecoxib) | 40 |
| Arm II (Placebo) | 34.1 |
Number of participants with a grade of 3 or higher during the treatment period. (NCT00081263)
Timeframe: Assessed every cycle while on treatment, 30 days after the last cycle of treatment
| Intervention | participants (Number) | |
|---|---|---|
| Gastrointestinal | Pain | |
| Arm I (Celecoxib) | 1 | 0 |
| Arm II (Placebo) | 0 | 1 |
4 trials available for celecoxib and HPV Infection
| Article | Year |
|---|---|
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adolescent; Adult; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Doub | 2017 |
Constitutive overexpression of the oncogene Rac1 in the airway of recurrent respiratory papillomatosis patients is a targetable host-susceptibility factor.
Topics: Adult; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Human papillomavi | 2012 |
T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis.
Topics: Case-Control Studies; Celecoxib; Chemokines; Humans; Larynx; Papilloma; Papillomavirus Infections; P | 2012 |
A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Fe | 2006 |
2 other studies available for celecoxib and HPV Infection
| Article | Year |
|---|---|
Juvenile recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: Initial report.
Topics: Adolescent; Antineoplastic Agents; Celecoxib; Child; Child, Preschool; Combined Modality Therapy; Cy | 2020 |
Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Human Papillomavirus Recombinant Vaccine Quadriv | 2019 |